Nektar Therapeutics (NKTR)Healthcare | Biotechnology | San Francisco, United States | NasdaqCM
68.32 USD
-2.04
(-2.899%) ⇩
(July 13, 2026, 4 p.m.
EDT)
After hours: 68.32 |
Hot Take ↕ | July 11, 2026, 4:36 a.m. EDT
The fundamental reality here is stark: Nektar Therapeutics is a speculative biotech play with no earnings, negative free cash flow, and a balance sheet that relies entirely on capital markets to survive. While the company has shown recent price resilience and a recovery in annual returns, the underlying business metrics—negative ROE and operating margins—remain deeply distressed. The massive disconnect between the current price and the analyst mean target is driven purely by the hope of a blockbuster drug approval, not by current profitability. Options activity confirms this binary outlook, with heavy positioning in deep OTM calls and deep ITM puts, indicating a wait-for-catalyst strategy rather than a conviction trade. For investors seeking stability or income, this is a hard pass; for those willing to gamble on a clinical success, the risk of permanent capital loss remains high. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.215938 |
| AutoETS | 0.220430 |
| MSTL | 0.222343 |
| AutoTheta | 0.293123 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 35% |
| H-stat | 7.77 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.169 |
| Excess Kurtosis | -0.87 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 24.892 |
| Revenue per Share | 2.847 |
| Market Cap | 2,308,261,632 |
| Forward P/E | -5.44 |
| Beta | 1.14 |
| Profit Margins | -284.18% |
| Website | https://www.nektar.com |
As of July 11, 2026, 4:36 a.m. EDT: Speculators are positioning for extreme volatility rather than a specific directional breakout. Call open interest is heavily skewed toward deep out-of-the-money strikes (100, 135, 160), while put open interest clusters around the $30-$45 range. This 'long gamma' structure suggests traders are betting on a binary event—likely clinical trial results—that could cause a massive gap up or a significant drop, rather than a steady trend.
| Attribute | Value |
|---|---|
| 52 Week Change | 1.8824253 |
| Address1 | 455 Mission Bay Boulevard South |
| All Time High | 1,670.4 |
| All Time Low | 6.15 |
| Ask | 77.66 |
| Ask Size | 1 |
| Audit Risk | 7 |
| Average Analyst Rating | 1.3 - Strong Buy |
| Average Daily Volume10 Day | 1,709,100 |
| Average Daily Volume3 Month | 1,176,355 |
| Average Volume | 1,176,355 |
| Average Volume10Days | 1,709,100 |
| Beta | 1.137 |
| Bid | 59.09 |
| Bid Size | 1 |
| Board Risk | 7 |
| Book Value | 19.551 |
| City | San Francisco |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 5 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 68.32 |
| Current Ratio | 10.207 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 69.99 |
| Day Low | 67.01 |
| Debt To Equity | 24.892 |
| Earnings Call Timestamp End | 1,778,187,600 |
| Earnings Call Timestamp Start | 1,778,187,600 |
| Earnings Timestamp | 1,778,184,000 |
| Earnings Timestamp End | 1,786,046,400 |
| Earnings Timestamp Start | 1,786,046,400 |
| Ebitda | -123,912,000 |
| Ebitda Margins | -2.22731 |
| Enterprise To Ebitda | -15.197 |
| Enterprise To Revenue | 33.848 |
| Enterprise Value | 1,883,089,664 |
| Eps Current Year | -9.5425 |
| Eps Forward | -12.5625 |
| Eps Trailing Twelve Months | -7.93 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fax | 415 339 5300 |
| Fifty Day Average | 68.8456 |
| Fifty Day Average Change | -0.5255966 |
| Fifty Day Average Change Percent | -0.007634426 |
| Fifty Two Week Change Percent | 188.24252 |
| Fifty Two Week High | 109.0 |
| Fifty Two Week High Change | -40.68 |
| Fifty Two Week High Change Percent | -0.37321103 |
| Fifty Two Week Low | 21.02 |
| Fifty Two Week Low Change | 47.3 |
| Fifty Two Week Low Change Percent | 2.2502377 |
| Fifty Two Week Range | 21.02 - 109.0 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 767,971,800,000 |
| Float Shares | 29,141,804 |
| Forward Eps | -12.5625 |
| Forward P E | -5.438408 |
| Free Cashflow | -107,228,376 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 63 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,782,864,000 |
| Gross Margins | 1.0 |
| Gross Profits | 55,633,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.00446 |
| Held Percent Institutions | 0.80373 |
| Implied Shares Outstanding | 33,786,032 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ir Website | http://ir.nektar.com/ |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,749,427,200 |
| Last Split Factor | 1:15 |
| Long Business Summary | Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. It develops rezpegaldesleukin, which is in Phase 2b to treat underlying immune system imbalance in people with autoimmune disorders and inflammatory diseases; NKTR-0165 to treat ulcerative colitis, vitiligo, and multiple sclerosis; NKTR-0166 to treat autoimmune disease; NKTR-422 to treat fibrotic diseases; and NKTR-255 to treat solid tumors and large b-cell lymphoma. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; and Merck KGaA. The company was incorporated in 1990 and is headquartered in San Francisco, California. |
| Long Name | Nektar Therapeutics |
| Market | us_market |
| Market Cap | 2,308,261,632 |
| Market State | PREPRE |
| Max Age | 86,400 |
| Message Board Id | finmb_29929 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | -158,098,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 2,377,185,211 |
| Number Of Analyst Opinions | 8 |
| Open | 69.71 |
| Operating Cashflow | -203,756,000 |
| Operating Margins | -3.52251 |
| Overall Risk | 4 |
| Payout Ratio | 0.0 |
| Peg Ratio | 0.31 |
| Phone | 415 482 5300 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 68.32 |
| Post Market Time | 1,783,981,118 |
| Previous Close | 70.36 |
| Price Eps Current Year | -7.1595497 |
| Price Hint | 2 |
| Price To Book | 3.4944503 |
| Price To Sales Trailing12 Months | 41.49087 |
| Profit Margins | -2.8418 |
| Quick Ratio | 9.916 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.3 |
| Region | US |
| Regular Market Change | -2.04 |
| Regular Market Change Percent | -2.89938 |
| Regular Market Day High | 69.99 |
| Regular Market Day Low | 67.01 |
| Regular Market Day Range | 67.01 - 69.99 |
| Regular Market Open | 69.71 |
| Regular Market Previous Close | 70.36 |
| Regular Market Price | 68.32 |
| Regular Market Time | 1,783,972,800 |
| Regular Market Volume | 666,682 |
| Return On Assets | -0.15285 |
| Return On Equity | -0.53597 |
| Revenue Growth | 0.038 |
| Revenue Per Share | 2.847 |
| Sand P52 Week Change | 0.20847368 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 2 |
| Shares Outstanding | 33,786,032 |
| Shares Percent Shares Out | 0.2041 |
| Shares Short | 6,896,119 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 4,612,979 |
| Short Name | Nektar Therapeutics |
| Short Percent Of Float | 0.2252 |
| Short Ratio | 5.42 |
| Source Interval | 15 |
| State | CA |
| Symbol | NKTR |
| Target High Price | 192.0 |
| Target Low Price | 80.0 |
| Target Mean Price | 153.25 |
| Target Median Price | 150.5 |
| Total Cash | 568,604,032 |
| Total Cash Per Share | 16.83 |
| Total Debt | 143,432,000 |
| Total Revenue | 55,633,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -7.93 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 62.201 |
| Two Hundred Day Average Change | 6.1189995 |
| Two Hundred Day Average Change Percent | 0.09837461 |
| Type Disp | Equity |
| Volume | 666,682 |
| Website | https://www.nektar.com |
| Zip | 94,158 |